Chao-Yie Yang, PhD¹, Xinrui Yuan^1*, Hua Jiang, PhD^2*, Jason C. Rech, PhD^3*, Denggang Fu, PhD^4*, Aaron Robida, PhD^5*, Krishani Rajanayake, PhD^6*, Hebao Yuan, PhD^6*, Bo Wen, PhD^6*, Duxin Sun, PhD^6*, Krishnapriya Chinnaswamy^5*, Jeanne A. Stuckey, PhD^5* and Sophie Paczesny, MD, PhD²

¹Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN
²Department of Microbiology and Immunology, Medical University of South Carolina College of Medicine, Charleston, SC
³Department of Internal Medicine, University ot Michigan, Ann Arbor, MI
⁴Department of Microbiology and Immunology, Medical University of South Carolina College of Medicine, Charleston
⁵Life Science Institute, University of Michigan, Ann Arbor, MI
⁶Pharmaceutical Sciences, University of Michigan College of Pharmacy, Ann Arbor, MI

Yankai Zhang, PhD¹, Celeste K. Kanne^1*, Michael J. Lacagnina, PhD^2*, Peter M. Grace, PhD^2*, Mark J. Burish, MD, PhD^3* and Vivien A. Sheehan, MD, PhD¹

¹Aflac Cancer and Blood Disorders Center, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
²The University of Texas MD Anderson Cancer Center, Houston, TX
³The University of Texas Health Science Center, Houston, TX

Céline Moison, PhD^1*, Deanne Gracias^1*, Julie Schmitt, PhD^1*, Simon Girard^1*, Simon Fortier, PhD^1*, Isabel Boivin^1*, Jean-Francois Spinella, PhD^1*, Tara Macrae^1*, Rejean Ruel^1*, Josee Hebert, MD^2,3,4,5*, Anne Marinier^1* and Guy Sauvageau, MD, PhD^5,6,7

¹Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada
²Department of Medicine, Université de Montréal, Montreal, QC, Canada
³Banque de Cellules Leucemiques du Quebec, Centre de Recherche de l’Hopital Maisonneuve-Rosemont, Montreal, QC, Canada
⁴Hopital Maisonneuve-Rosemont, Departement d’Hematologie-Oncologie, Montreal, QC, Canada
⁵The Leucegene Project at the Institute for Research in Immunology and Cancer (IRIC), Montréal, QC, Canada
⁶Hôpital Maisonneuve-Rosemont, Département d’Hématologie-Oncologie, Montréal, QC, Canada
⁷Département de Médecine, Université de Montréal, Montreal, QC, Canada

Hojjat Alizadeh Zeinabad, PhD^1*, Wen Jie Yeoh, PhD student^2*, Philippe Krebs, PhD^2*, Carsten Riether, PhD³, Mihai Lomora, PhD^4,5*, Yara Banz, MD, PhD^2* and Eva Szegezdi, PhD^1,4*

¹Apoptosis Research Centre, School of Biological and Chemical Sciences, University of Galway, Galway, Ireland
²Institute of Pathology, University of Bern, Bern, Switzerland
³Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland
⁴CURAM Science Foundation Ireland Centre for Research in Medical Devices, University of Galway, Galway, Ireland
⁵School of Biological and Chemical Sciences, University of Galway, Galway, Ireland

Deanne Gracias^1*, Céline Moison, PhD^1*, Rodrigo Mendoza-Sanchez^2*, Simon Fortier, PhD^1*, Simon Girard^1*, Jean-Francois Spinella, PhD^1*, Tara Macrae^1*, Bounkham Thavonekham^2*, Rejean Ruel^1*, Josee Hebert, MD^3,4,5,6*, Anne Marinier^1* and Guy Sauvageau, MD, PhD^7,8,9

¹Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montréal, QC, Canada
²Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada
³Quebec Leukemia Cell Bank, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
⁴Department of Medicine, Université de Montréal, Montreal, QC, Canada
⁵The Leucegene Project at the Institute for Research in Immunology and Cancer (IRIC), Montréal, QC, Canada
⁶Hopital Maisonneuve-Rosemont, Departement d’Hematologie-Oncologie, Montreal, QC, Canada
⁷Hôpital Maisonneuve-Rosemont, Département d’Hématologie-Oncologie, Montréal, QC, Canada
⁸Département de Médecine, Université de Montréal, Montreal, QC, Canada
⁹Projet Leucegene, Institut de Recherche en Immunologie et en Cancerologie (IRIC), Universite de Montreal, Montreal, QC, Canada

Son Tran^1*, Ritul Sharma, MSc^1*, Chunfen Zhang, MD^1*, Ranjan Maity, PhD^1*, Amy J. Johnson, PhD², Melanie M. Frigault, PhD², Raquel Izumi, PhD², Ahmed Hamdy, MD², Beatrix Stelte-Ludwig, PhD^3*, Nizar J. Bahlis, MD¹, Paola Neri, MD, PhD¹ and Aru Narendran, MD, PhD^1*

¹Department of Oncology, University of Calgary, Calgary, AB, Canada
²Vincerx Pharma Inc, Palo Alto, CA
³Vincerx Pharma GmbH, Monheim, Germany

Karina Thiel-Klare^1*, Alexander Rogers^2*, Ryan Boston^3*, Jeffrey W. Tyner⁴ and Bill H. Chang, MD, PhD⁵

¹Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
²OHSU, Portland, OR
³Pediatrics, OHSU, Portland, OR
⁴Knight Cancer Institute, Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR
⁵Knight Cancer Institute, Division of Pediatric Hematology and Oncology, Oregon Health & Science University, Portland, OR

Caner Saygin, MD¹, Bartholomew Eisfelder, PhD^2*, Giorgia Giordano^3*, Anika Thomas-Toth^4*, Yi Chen, PhD^5*, Felai Tan, PhD, MD^6*, Stephen P. Anthony, DO⁵, Yu Chen, MD, PhD^5*, Yue Shen, PhD^5*, James LaBelle, MD, PhD⁷ and Wendy Stock, MD⁴

¹Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
²Section of Hematology/Oncology, University of Chicago, Chicago, IL
³University of Chicago Hospitals, Chicago, IL
⁴University of Chicago, Chicago, IL
⁵Newave Pharmaceutical Inc., Pleasanton, CA
⁶Newave Pharmaceuticals Inc., Pleasanton, CA
⁷The University of Chicago Medicine, Chicago, IL

Mengyao Wang^1*, Danrong Hu^2*, Ying Qu, PhD^1*, Zhiyong Qian, PhD^3* and Ting Niu¹

¹Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China, Chengdu, Sichuan, China, China
²State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center, Chengdu, Sichuan, 610041, P. R. China, Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, China, China
³State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Collaborative Innovation Center, Chengdu, Sichuan, 610041, P. R. China, Chengdu, Sichuan, China, China

Mithun Milind Sarangdhar, PhD^1*, Eric O'Brien, BSc^1*, Brett VanCauwenbergh, BSc^1*, Jackson Alexander^1*, Caroline Theile^1*, Mitali Basu, MSc^1*, Mayur Sarangdhar, PhD^1,2*, William Seibel, PhD^1* and John P Perentesis, MD³

¹Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute, Cincinnati, OH
²Cincinnati Children's Hospital Medical Center, Division of Biomedical Informatics, Cincinnati, OH
³Cancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH

Erin Hertlein, PhD¹, Chad Bennett, PhD^2*, Ola A Elgamal, PhD, BSc¹, Sandip Vibhute, PhD^3*, Sharyn Baker, PharmD PhD⁴, Thomas E Goodwin, PhD^5*, Don M. Benson Jr., MD⁶, Christopher Coss, PhD^7*, Jeffrey Patrick, PharmD^2*, Gerald Hilinski, PhD^2* and John C. Byrd, MD¹

¹Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
²Drug Development Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH
³Medicinal Chemistry Shared Resource, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁴Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus
⁵Hendrix College, Conway, AR
⁶Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH
⁷Division of Pharmaceutics and Pharmacology, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, Columbus, OH

Juho J. Miettinen, PhD^1*, Tanja Ruokoranta, MSc^1*, Vilma Ikonen, MSc^2*, Maiju-Emilia Huppunen, MSc^1*, Klara Acs, PhD^3*, Fredrik Lehmann, PhD^3* and Caroline A. Heckman, PhD¹

¹Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
²Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
³Oncopeptides AB, Stockholm, Sweden

Kim Anh Giang^1*, Mizuha Kanaya^2,3*, Thorstein Boxaspen, MD^2,3,4*, Minoru Kanaya^2,3, Silje Zandstra Krokeide^2,3*, Yumei Diao^5*, Fredrik Schjesvold, MD, PhD^4,6, Fredrik Lehmann^5*, Johan Nilvebrant^1*, Stefan Svensson Gelius^5*, Karl-Johan Malmberg^2,3* and Per-Åke Nygren^1,7*

¹Department of Protein Science, Div. Protein Engineering, AlbaNova University Center, KTH Royal Institute of Technology, Stockholm, Sweden
²Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
³Institute of Clinical Medicine, University of Oslo, Oslo, Norway
⁴Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
⁵Oncopeptides AB, Stockholm, Sweden
⁶KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway
⁷Science For Life Laboratory, Solna, Sweden

Marissa L Calbert, BSc^1,2, Gurushankar Chandramouly, PhD^1*, Tatiana Kent, PhD^1*, Clare M Adams, PhD^3*, Mrityunjay Tyagi, PhD^1*, Yifan Wang, PhD^4*, John Krais, PhD^4*, Hoora Shaghaghi, PhD^5*, Jessica Atkins, BSc^2*, Tomasz Skorski, MD, PhD², Neil Johnson, PhD^4*, Christine M Eischen, PhD³ and Richard Pomerantz, PhD^1*

¹Sidney Kimmel Cancer Center, Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, PA
²Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA
³Sidney Kimmel Cancer Center, Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA
⁴Fox Chase Cancer Center, Philadelphia, PA
⁵Center for Translational Medicine, Thomas Jefferson University, Philadelphia, PA